Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.

Journal of virology - 1 Nov 2006

Baxter John D, Schapiro Jonathan M, Boucher Charles A B, Kohlbrenner Veronika M, Hall David B, Scherer Joseph R, Mayers Douglas L

Abstract excerpt

Tipranavir is a novel, nonpeptidic protease inhibitor of human immunodeficiency virus type 1 (HIV-1) with activity against clinical HIV-1 isolates from treatment-experienced patients. HIV-1 genotypic and phenotypic data from phase II and III clinical trials of tipranavir with protease inhibitor-experienced patients were analyzed to determine the association of protease mutations with reduced susceptibility and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to HIV Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Protease

Share to HIV Protease Inhibitors

Share to Pyridines

Share to Pyrones

Share to Regression Analysis

Share to Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 16928764
DOI: 10.1128/JVI.00712-06
PMCID: PMC1641746

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.PMID 16928764Read ↗

Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.Semantic proximity Read ↗

Tipranavir.Semantic proximity Read ↗

Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir.Semantic proximity Read ↗

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.Semantic proximity Read ↗

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients.Semantic proximity Read ↗

Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.Semantic proximity Read ↗

Improving the prediction of virological response to tipranavir: the development and validation of a tipranavir-weighted mutation score.Semantic proximity Read ↗

Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples.Semantic proximity Read ↗

Identification of Genotypic Changes in Human Immunodeficiency Virus Protease That Correlate with Reduced Susceptibility to the Protease Inhibitor Lopinavir among Viral Isolates from Protease Inhibitor-Experienced PatientsSemantic proximity Read ↗

Tipranavir: a ritonavir-boosted protease inhibitor.Semantic proximity Read ↗

HIV-1 protease mutations and protease inhibitor cross-resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.